Alzheimer's disease

Alzheimer's disease is a progressive brain disorder that slowly destroys memory and thinking skills, and eventually the ability to carry out the simplest tasks. It is the most common cause of dementia among older adults. The disease is named after Dr. Alois Alzheimer, who noticed changes in the brain tissue of a woman who had died of an unusual mental illness in 1906.

Symptoms of Alzheimer's disease usually develop slowly and worsen over time, becoming severe enough to interfere with daily tasks. The most common early symptom is difficulty remembering newly learned information. As the disease advances, symptoms can include problems with language, disorientation (including easily getting lost), mood swings, loss of motivation, and behavioral issues.

The exact cause of Alzheimer's disease is not fully understood, but it is believed to result from a combination of genetic, environmental, and lifestyle factors that affect the brain over time. There is currently no cure for Alzheimer's disease, but there are medicines approved by the U.S. Food and Drug Administration (FDA) that can help manage some symptoms and slow the progression of the disease.

Alzheimer's disease is classified into two types: early-onset Alzheimer's disease, which occurs between a person's 30s and mid-60s, and late-onset Alzheimer's disease, which occurs after a person's mid-60s. Both types can be related to a person's genes in some way.

Diagnosis of Alzheimer's disease is based on a comprehensive medical evaluation that includes a thorough medical history, physical and neurological exams, mental status tests, and other diagnostic tests such as brain imaging. The disease is diagnosed when all other possible causes of dementia symptoms have been ruled out.

Treatment for Alzheimer's disease includes medicines that can help with symptoms and newer medicines that can help slow decline in thinking and functioning. The U.S. Food and Drug Administration (FDA) has approved lecanemab (Leqembi) and donanemab (Kisunla) for people with mild Alzheimer's disease and mild cognitive impairment due to Alzheimer's disease.

The prognosis for people with Alzheimer's disease varies, but on average, people with the disease live between three and 11 years after diagnosis. However, some people live 20 years or more. The disease can be devastating for the person with Alzheimer's and their family and caregivers.

Research into the causes, treatments, and prevention of Alzheimer's disease is ongoing. Scientists are studying biomarkers (biological signs of disease found in brain images, cerebrospinal fluid, and blood) to detect early changes in the brains of people with mild cognitive impairment and in cognitively normal people who may be at greater risk for Alzheimer's.

Comments

Non-invasive BCIs (EEG-based)

This is an exciting and rapidly developing field within neurotechnology. 1. Introduction to Non-invasive BCIs: - Definition and basic concepts - Advantages over invasive BCIs - Historical development 2. Principles of Electroencephalography (EEG): - Neural origins of EEG signals - Frequency bands (delta, theta, alpha, beta, gamma) - Spatial and temporal resolution 3. EEG Recording Techniques: - Electrode placement (10-20 system) - Types of electrodes (wet, dry, active) - Amplification and digitization of signals - Artifact reduction techniques 4. Signal Processing in EEG-based BCIs: - Preprocessing (filtering, artifact removal) - Feature extraction methods: * Time-domain features * Frequency-domain features * Time-frequency analysis * Spatial filter...

Tumors of the Nervous System complete tutorial

Tumors of the nervous system can be classified into two broad categories: primary tumors, which originate in the nervous system, and secondary tumors, which originate elsewhere in the body and spread to the nervous system. Primary tumors of the nervous system can be further divided into benign (non-cancerous) and malignant (cancerous) tumors. **Benign Tumors of the Nervous System:** 1. **Meningiomas**: These are the most common type of benign brain tumor. They arise from the meninges, the membranes that surround the brain and spinal cord. 2. **Schwannomas**: These tumors arise from Schwann cells, which produce the myelin sheath that surrounds and insulates nerve fibers. 3. **Neuromas**: These are benign tumors that arise from nerve tissue. 4. **Pituitary Adenomas**: These are benign tumors that arise from the pituitary gland, a small gland at the base of the brain that produces hormones. 5. **Craniopharyngiomas**: These are benign tumors that arise near the pituitary gland. ...

Neuralink History

Neuralink, founded by Elon Musk in 2016, has been at the forefront of developing brain-computer interface (BCI) technology, aiming to create a seamless connection between the human brain and computers. The company's journey has been marked by significant milestones, challenges, and breakthroughs. In 2019, Neuralink introduced its first prototype, a device that could record and stimulate brain activity. This was followed by the development of a robot capable of performing the delicate surgery required for implanting the device. The robot's design was a collaboration between Neuralink and Woke Studios, showcasing the company's commitment to innovation. In January 2024, Neuralink achieved a major milestone when it announced the successful implantation of its brain-computer interface in a human subject. This marked the beginning of a new era in BCI technology, as the device allowed the subject to control a computer mouse using their thoughts. The company has since continue...

Neuro Technology

Search This Blog